Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05205837
Other study ID # H-20036287
Secondary ID 2020-002612-52
Status Terminated
Phase Phase 4
First received
Last updated
Start date November 24, 2021
Est. completion date August 15, 2023

Study information

Verified date February 2024
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall objective of this randomized trial is to investigate the effects of treatment of AAS- induced male hypogonadism with combined therapy of letrozole and hCG compared with placebo on reproductive hormone levels, adherence to cessation of AAS use, fertility, cardiac function and quality of life.


Description:

A randomized, double-blinded, clinical, placebo-controlled trial enrolling 60 male illicit AAS users with documented AAS-induced hypogonadism after a period > 12 weeks of AAS cessation or a negative urine AAS doping test. Participants will be randomized to two study groups; 24 weeks of treatment with either tablet letrozole (femar®) initial dose of 2.5 mg each day versus tablet placebo. After an initial treatment period of four weeks, intramuscular injections with either hCG, initial dose 1500 IE twice weekly (letrozole group) or isotonic saline twice weekly (placebo group) will be added to therapy if plasma total testosterone level has not increased to target plasma level. Following 24 weeks of therapy, all participants will be observed for another 26 weeks without therapy. The study will have one trial center of recruitment: Department of Endocrinology, Rigshospitalet. Following participation in the study, all participants will be offered referral to an endocrine outpatient clinic if they still display clinical and biochemical signs of male hypogonadism. A healthy group of 30 young lean eugonadal men, who have never used AAS, will be enrolled as control participants and undergo a screening visit and one visit including same procedures as the screening and randomization visits.


Recruitment information / eligibility

Status Terminated
Enrollment 8
Est. completion date August 15, 2023
Est. primary completion date August 15, 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - • Male sex - 18 - 50 years of age - Hypogonadism following observational period of a minimum of 12 weeks since AAS discontinuation OR hypogonadism with a urine sample negative for AAS analyses at screening visit: plasma total testosterone = 10 nmol/L AND featuring at least one symptom of male hypogonadism using IIEF in terms of erectile function (IIEF: Q1 - Q5 + Q15; total score < 26) and/or sexual desire (IIEF: Q11 + Q12; total < 7) (1) and/or ADAM questionnaire (YES to three questions other than question 1 and 7) and/or regular use of medical treatment for erectile dysfunction. - Motivation for permanent AAS cessation Exclusion Criteria: - Established cardiovascular disease - Established diabetes of any kind 384 - Congenital hypogonadal conditions (cryptorchidism, Klinefelter's disease, Kallmann's disease etc.) - Previous established hypogonadal conditions due to other causes than illicit use of AAS - Current or previous treatment with testosterone on other indication than AAS-induced male hypogonadism - Abnormal puberty development (small testes, late or absent pubic hairing, late or absent deepening of voice, etc.) - Current or previous pituitary diseases including pituitary tumors - Current or previous tumors of the hypothalamus - Current or former testicular cancer - Current or previous prostate cancer - Current or previous breast cancer - Other cancers unless complete remission = 5 year - Other concomitant disease or makes the patient unsuitable to participate in the study - Severely impaired liver function - Allergy or hypersensitivity to the active substance (letrozole) or excipients of Letrozol "Accord"® listed in Appendix D - Allergy or hypersensitivity to the active substance (hCG) or excipients of Brevactid® listed in Appendix D - Established Lapp lactase deficiency or glucose/galactose malabsorption - Severe venous phlebitis or current or previous venous thromboembolism - Inguinal hernia - treatment which according to the investigators' assessment - Simultaneous participation in another clinical study - Unable to follow treatment instructions in terms of study medication instructions - Ongoing criminal behavior in terms of violence or illicit distribution of drugs - Currently or in the foreseeable future included in anti-doping programs

Study Design


Intervention

Drug:
Letrozole 2.5mg, hCG
Drug -Treatment Intramuscular injektion - Treatment
Placebo
Drug - Placebo Intramuscular injektion - placebo

Locations

Country Name City State
Denmark Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in plasma total testosterone concentration after 24 weeks from baseline 24 weeks
Secondary Number of participants who adhere to AAS cessation after 24 and 50 weeks from baseline 24 and 50 weeks
Secondary Change in total plasma testosterone concentration after 50 weeks from baseline 50 weeks
Secondary Change in plasma total testosterone secretion in response to hCG stimulation after 24 and 50 weeks from baseline 24 and 50 weeks
Secondary Change in basal plasma pituitary gonadotropins, LH and FSH, after 24 and 50 weeks from baseline 24 and 50 weeks
Secondary Change in secretion of plasma pituitary gonadotropins, LH and FSH, in response to GnRH stimulation after 24 and 50 weeks from baseline 24 and 50 weeks
Secondary Change in sperm count after 24 and 50 weeks from baseline 24 and 50 weeks
Secondary Change in sperm motility after 24 and 50 weeks from baseline 24 and 50 weeks
Secondary Change in sperm morphology after 24 and 50 weeks from baseline 24 and 50 weeks
Secondary Change in sperm acrosome reaction after 24 and 50 weeks from baseline 24 and 50 weeks
Secondary Change in sperm DNA fragmenting after 24 and 50 weeks from baseline 24 and 50 weeks
Secondary Change in testicular size assessed using ultrasound after 24 and 50 weeks 24 and 50 weeks
Secondary Change in questionnaire score IIEF (erectile function and libido) from baseline and after 24 and 50 weeks 24 and 50 weeks
Secondary Change in questionnaire score ADAM (hypogonadism) from baseline and after 24 and 50 weeks 24 and 50 weeks
Secondary Change in questionnaire score of Major Depression Inventory (MDI) (depression) from baseline and after 24 and 50 weeks 24 and 50 weeks
Secondary Change in questionnaire score of (GAD7) (anxiety) from baseline and after 24 and 50 weeks 24 and 50 weeks
Secondary Change in questionnaire score of Buss-Perry Aggression scale (BPA) (hostility and aggression) from baseline and after 24 and 50 weeks 24 and 50 weeks
Secondary Change in questionnaire score of COBRA (Cognitive complaints in bipolar disorder rating assessment) from baseline and after 24 and 50 weeks 24 and 50 weeks
Secondary Change in questionnaire score of the Health Assessment Short Form-36 questionnaire from baseline and after 24 and 50 weeks 24 and 50 weeks
Secondary Change in questionnaire score of Body-Q 349 (Perception of own body) from baseline and after 24 and 50 weeks 24 and 50 weeks
Secondary Change in questionnaire score of the Inventory of Interpersonal Problems 32-item (IIP32) from baseline and after 24 and 50 weeks 24 and 50 weeks
Secondary Change in myocardial function assessed by myocardial flow reserve (mL/min/gr) by Rb-82 PET from baseline and after 24 and 50 weeks 24 and 50 weeks
Secondary Change in cardiac systolic function assessed using left ventricular ejection fraction (LVEF) obtained using echocardiography and 24 and 50 weeks from baseline. 24 and 50 weeks
Secondary Change in cardiac systolic function assessed using left ventricular global longitudinal strain (GLS) obtained using echocardiography and 24 and 50 weeks from baseline. 24 and 50 weeks
Secondary Change in cardiac structure (left ventricular mass) obtained using echocardiography and 24 and 50 weeks from baseline. 24 and 50 weeks
See also
  Status Clinical Trial Phase
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Terminated NCT02419105 - Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors Phase 3
Withdrawn NCT02137265 - Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism N/A
Completed NCT02222558 - Oral Testosterone for the Treatment of Hypogonadism in Males Phase 2
Completed NCT02233751 - Pharmacokinetic Study of Subcutaneous Testosterone Enanthate Phase 1
Completed NCT01887418 - Pharmacokinetic Study of Testosterone Enanthate Phase 1/Phase 2
Terminated NCT01092858 - NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH) Phase 4
Completed NCT00624624 - Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism N/A
Completed NCT00752869 - Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Phase 4
Completed NCT00613288 - Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism N/A
Completed NCT00838838 - Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis N/A
Completed NCT00119483 - Older Men and Testosterone N/A
Completed NCT00004438 - Leuprolide in Treating Adults With Hypogonadotropism N/A
Withdrawn NCT00398034 - Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study. Phase 2
Completed NCT02921386 - The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate Phase 2
Completed NCT02937740 - Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Phase 4
Completed NCT01717768 - Oral Testosterone for the Treatment of Hypogonadism Phase 2
Terminated NCT01460654 - Testosterone and Alendronate in Hypogonadal Men Phase 2
Completed NCT00998933 - Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure Phase 1
Completed NCT00663793 - ORAL T-6: Oral Androgens in Man-6 Phase 1